rh 1

RH1 (NSC 697726) is a bioreductive anticancer compound that exhibits dose-dependent biphasic effects in vitro, inducing apoptosis at higher doses and senescence at lower doses.

Ginsenoside Rh1 (Sanchinoside B2) , one of the main constituents of Panax ginseng, exhibits anti-inflammatory effect.

(20R)-Ginsenoside Rh1 (20(R)-Ginsenoside Rh1) can inhibit the thrombin-induced conversion of fibrinogen to fibrin.

(20R)-Ginsenoside Rh1 (Standard) is a reference standard for research and analysis in studies involving (20R)-Ginsenoside Rh1. (20R)-Ginsenoside Rh1 (20(R)-Ginsenoside Rh1) can inhibit the thrombin-induced conversion of fibrinogen to fibrin.

Ginsenoside Rh1 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside Rh1. Ginsenoside Rh1 (Sanchinoside B2) , one of the main constituents of Panax ginseng, exhibits anti-inflammatory effect.

20(E)-Sanchinoside B1 (Standard) is a reference standard for research and analysis in studies involving 20(E)-Sanchinoside B1. 20(E)-Sanchinoside B1 is a triterpenoid compound.

[D-Leu6, Val7]-LH-RH (1-9) Ethyl Amide is an LH-RH peptide analogue.

[D-Glp1,D-Phe2,D-Trp3,6]-LH-RH, a luteinizing hormone-releasing hormone (LHRH) analogue, acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist [1].

(Z-IETD)2-Rh 110 is a fluorescent substrate for caspase-8 (λex= 488 nm, λem= 523 nm) and can be used to measure caspase-8 activity and monitor apoptosis.

RJW100 is a compound that acts as a potent agonist of liver receptor homolog 1 (LRH-1, NR5A2) and steroidogenic factor-1 (SF-1, NR5A1), exhibiting pEC50 values of 6.6 and 7.5, respectively. Additionally, RJW100 induces robust activation of the miR-200c (miRNA-200c, microRNA-200c) promoter.

(Iso)-RJW100 is a potent liver receptor homolog 1 (LRH-1, NR5A2) and steroidogenic factor-1 (SF-1, NR5A1) agonist with pEC 50 s of 6.4 and 7.2, respectively.

LRH-1 Inhibitor-3 is an antagonist that inhibits LRH-1 transcriptional activity, reducing the expression of target genes associated with cell growth and proliferation, such as SHP (small heterodimer partner), cyclin E1 (CCNE1), and G0S2, and inhibiting the proliferation of human pancreatic, colon, and breast adenocarcinoma cells.

KRH102140 is a PHD2 activator that reduces angiogenesis by inhibiting HIF-1alpha, used in cardiovascular disease research.

Doxepin D3 Hydrochloride is a deuterium-labeled doxepin hydrochloride.Doxepin hydrochloride is an oral active tricyclic antidepressant used as a sedative.Doxepin hydrochloride is also an effective CYP450 inhibitor, significantly inhibiting CYP450 2C19 and

ML-180 (SR1848) is a potent inverse agonist of the orphan nuclear receptor liver receptor homolog 1 (LRH-1; NR5A2) with an IC50 of 3.7 μM.

PARP14 inhibitor H10 is a selective inhibitor against PARP14 with IC50 of 490 nM

LRH-1 agonist-1 (compound 74) acts as an agonist for LRH-1, exhibiting an IC50 value of 47 μM.

RH1115 is a modulator of autophagolysosomes. It induces changes in the characteristics of LAMP1 vesicles and alters lysosomal localization.

RH12 is a dual inhibitor of SARS-CoV-2-related RNA-dependent RNA polymerase (RdRp, IC50 of 4.42 nM) and human transmembrane serine protease 2 (TMPRSS2, IC50 of 4.2 nM). It demonstrates antiviral activity by inhibiting viral replication and absorption, showing 90.5% virucidal effect in Vero-E6 cells. Additionally, RH12 inhibits Calu-3 cell viability with an IC50 of 17.5 nM.

DLPC is an LRH-1 agonist ligand. DLPC is a phospholipid for biological study[1][2].

LRH-1 modulator-1 is a potent modulator/agonist of LRH-1 (liver receptor homolog-1). LRH-1 modulator-1 induces the anti-inflammatory cytokine IL-10 and exhibits inhibition of the inflammatory cytokines IL-1b and TNFa. LRH-1 modulator-1 has anti-inflammatory activity in intestinal-like organs.

KRH-1636 is an orally active, selective and extremely potent CXC chemokine receptor 4 antagonist. KRH-1636 exhibits a potent and selective anti-HIV-1 activity. KRH-1636 efficiently blocked replication of various T cell line-tropic (X4) HIV type 1 (HIV-1) in MT-4 cells and peripheral blood mononuclear cells through the inhibition of viral entry and membrane fusion via the CXC chemokine receptor (CXCR)4 coreceptor but not via CC chemokine receptor 5. KRH-1636 also inhibits binding of the CXC chemokine, stromal cell-derived factor 1alpha, to CXCR4 specifically and subsequent signal transduction. KRH-1636 prevented monoclonal antibodies from binding to CXCR4 without down-modulation of the coreceptor. KRH-1636 seems to be a promising agent for the treatment of HIV-1 infection.

QC-308 HCl is a novel Heme Oxygenase-1 Inhibitor (HO-1 IC50=0.27μM; HO-2 IC50=0.46μM).

KRH102053 is a HIF-1alpha inhibitor. KRH102053 decreased the protein level of HIF-1alpha and the mRNA levels of HIF-regulated downstream target genes, such as vascular endothelial growth factor, aldolase A, enolase 1 and monocarboxylate transporter 4. Consistent with these results, KRH102053 also inhibited the rates of HIF-related migration and invasion of HOS cells as well as the degree of tube formation in human umbilical vein endothelium cells.